Editorial: FDA restrictions threaten legacy drugs

The FDA in June began to mandate that unapproved legacy drugs, such as quinine, must undergo the same approval process that new drugs go through as part of the agency's new strategy to improve drug safety. These types of longstanding drugs could be withdrawn for the market unless they submit to the FDA's expensive new drug application process, leading The Wall Street Journal to call for the FDA to give them a "special regulatory pathway" for approval.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC